Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

735.07 +10.20 (+1.41%)
Streaming Delayed Price Updated: 11:57 AM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 780,558
Open 723.48
Bid (Size) 734.74 (4)
Ask (Size) 735.54 (4)
Prev. Close 724.87
Today's Range 721.00 - 737.45
52wk Range 370.68 - 800.78
Shares Outstanding N/A
Dividend Yield 0.61%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ResMed Soars To Eight-Month High As Quarterly Report Wipes Out Weight-Loss Woes
ResMed is the biggest maker of CPAPs in the U.S., and says the growing popularity of weight-loss drugs could help diagnosis rates. 
Via Investor's Business Daily
Dividend Legends: 3 Stocks With Over 100 Years of Payouts
Dividend payers are companies that have stood the test of time and these dividend stocks with 100+ years of payouts lead them all. 
Via InvestorPlace

Performance

YTD
+24.13%
+24.13%
1 Month
-5.14%
-5.14%
3 Month
+17.12%
+17.12%
6 Month
+29.39%
+29.39%
1 Year
+95.36%
+95.36%

More News

Read More
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
Via Investor's Business Daily
Don’t Miss Out! 3 Top-Tier Blue-Chip Growth Stocks for Your Must-Buy List
Via InvestorPlace
Which Companies Will Join the Trillion-Dollar Team in 2024? Our 3 Best Guesses
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Market Whales and Their Recent Bets on LLY Options
Via Benzinga
Exploring The Competitive Space: Eli Lilly and Co Versus Industry Peers In Pharmaceuticals
Via Benzinga
What Are Pricing Strategies for Ozempic And Wegovy With Potential Medicare Coverage Expansion? Senate Committee Questions Novo Nordisk
Via Benzinga
Meet Eli Lilly's Secret Weapon in the Billion-Dollar Weight-Loss Drug Market
Via The Motley Fool
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
Via InvestorPlace
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Via The Motley Fool
REITs Q1 Earnings Begin On Solid Note
Via Benzinga
Better Buy: Pfizer vs. Viking Therapeutics
Via The Motley Fool
3 Stocks With the Potential to Surpass Analyst Expectations for 2024
Via InvestorPlace
Eli Lilly Aims To Close Supply-Demand Gap For Zepbound/Mounjaro As It Acquires Manufacturing Facility From Nexus Pharma
Via Benzinga
7 High-Flying Stocks That Are Majorly Overdue for a Pullback
Via InvestorPlace
Changing Frugal Eating Habits - How Novo Nordisk/Eli Lilly's Weight Loss Drugs Reshaping Food Spending
Via Benzinga
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Via MarketBeat
6 Stocks Positioned to Soar as Investors Focus on MASH
Via TheNewswire.com
Capturing Consumer Spending on Health Care with XLV
Via News Direct
Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential
Via The Motley Fool
3 Relatively Safe Growth Stocks You Can Buy and Hold
Via The Motley Fool
SPDR ETF Report For Friday, April 19
Via Talk Markets
Topics ETFs
Stock Market Sells Off; Taiwan Semi, ASML, Netflix, Tesla In Focus: Weekly Review
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Strong Buy Alert: 7 No-Brainer Stocks to Scoop Up Now
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.